BioVie Inc
BIVI
查看详细走势图
1.130USD
+0.070+6.60%
收盘 02/06, 16:00（美东）报价延迟15分钟
8.52M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.60%
5天
-0.88%
1月
-16.30%
6月
-61.17%
今年开始到现在
-2.59%
1年
-94.11%
查看详细走势图
TradingKey BioVie Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
BioVie Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名195/392位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价12.00。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
BioVie Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
BioVie Inc亮点
亮点风险
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
估值高估
公司最新PE估值-0.18，处于3年历史高位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值213.53K
分析师目标
根据
0
位分析师
--
评级
12.000
目标均价
+867.74%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BioVie Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BioVie Inc简介
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
公司代码BIVI
公司BioVie Inc
CEODo (Viet Cuong Viet)
网址https://www.bioviepharma.com/
相关品种
